Generation of “Off-the-Shelf” Natural Killer Cells from Peripheral Blood Cell-Derived Induced Pluripotent Stem Cells

Stem Cell Reports

Volumn 9, Issue 6, 2017, Pages 1796-1812

  Zeng, Jieming ^a   Tang, Shin Yi ^a,b   Toh, Lai Ling ^a   Wang, Shu ^a,b  

^a INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

cancer; cell therapy; cytotoxicity; immunotherapy; induced pluripotent stem cells; killer cell immunoglobulin like receptors; natural killer cells; peripheral blood cells

Indexed keywords

CD34 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR;

ARTICLE; BLOOD CELL; CANCER CELL; CELL DIFFERENTIATION; CELL EXPANSION; CELL FUNCTION; CELL STRUCTURE; CRYOPRESERVATION; CYTOTOXICITY; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN CELL; HUMAN EMBRYONIC STEM CELL; INDUCED PLURIPOTENT STEM CELL; NATURAL KILLER CELL; NUCLEAR REPROGRAMMING; OP9 CELL LINE; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; UMBILICAL CORD BLOOD CELL; CELL CULTURE TECHNIQUE; CELL PROLIFERATION; CYTOLOGY; EMBRYOID BODY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PERIPHERAL BLOOD STEM CELL; PROCEDURES;

CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL PROLIFERATION; EMBRYOID BODIES; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; INDUCED PLURIPOTENT STEM CELLS; KILLER CELLS, NATURAL; PERIPHERAL BLOOD STEM CELLS; RECEPTORS, KIR;

EID: 85034621729     PISSN: 22136711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.stemcr.2017.10.020     Document Type: Article

References (32)

1. Benson, D.M. Jr., Caligiuri, M.A., Killer immunoglobulin-like receptors and tumor immunity. Cancer Immunol. Res. 2 (2014), 99–104.
2. Benson, D.M. Jr., Hofmeister, C.C., Padmanabhan, S., Suvannasankha, A., Jagannath, S., Abonour, R., Bakan, C., Andre, P., Efebera, Y., Tiollier, J., et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 120 (2012), 4324–4333.
3. Benson, D.M. Jr., Cohen, A.D., Jagannath, S., Munshi, N.C., Spitzer, G., Hofmeister, C.C., Efebera, Y.A., Andre, P., Zerbib, R., Caligiuri, M.A., A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma. Clin. Cancer Res. 21 (2015), 4055–4061.
4. Colucci, F., Caligiuri, M.A., Di Santo, J.P., What does it take to make a natural killer?. Nat. Rev. Immunol. 3 (2003), 413–425.
5. De Obaldia, M.E., Bhandoola, A., Transcriptional regulation of innate and adaptive lymphocyte lineages. Annu. Rev. Immunol. 33 (2015), 607–642.
6. Domogala, A., Madrigal, J.A., Saudemont, A., Natural killer cell immunotherapy: from bench to bedside. Front. Immunol., 6, 2015, 264.
7. Fujisaki, H., Kakuda, H., Shimasaki, N., Imai, C., Ma, J., Lockey, T., Eldridge, P., Leung, W.H., Campana, D., Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 69 (2009), 4010–4017.
8. Gonzalez, F., Boue, S., Izpisua Belmonte, J.C., Methods for making induced pluripotent stem cells: reprogramming a la carte. Nat. Rev. Genet. 12 (2011), 231–242.
9. Jaleco, A.C., Neves, H., Hooijberg, E., Gameiro, P., Clode, N., Haury, M., Henrique, D., Parreira, L., Differential effects of Notch ligands Delta-1 and Jagged-1 in human lymphoid differentiation. J. Exp. Med. 194 (2001), 991–1002.
10. Karanu, F.N., Murdoch, B., Miyabayashi, T., Ohno, M., Koremoto, M., Gallacher, L., Wu, D., Itoh, A., Sakano, S., Bhatia, M., Human homologues of Delta-1 and Delta-4 function as mitogenic regulators of primitive human hematopoietic cells. Blood 97 (2001), 1960–1967.
11. Knorr, D.A., Ni, Z., Hermanson, D., Hexum, M.K., Bendzick, L., Cooper, L.J., Lee, D.A., Kaufman, D.S., Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl. Med. 2 (2013), 274–283.
12. Koehl, U., Brehm, C., Huenecke, S., Zimmermann, S.Y., Kloess, S., Bremm, M., Ullrich, E., Soerensen, J., Quaiser, A., Erben, S., et al. Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol. Front. Oncol., 3, 2013, 118.
13. Lancaster, M.A., Renner, M., Martin, C.A., Wenzel, D., Bicknell, L.S., Hurles, M.E., Homfray, T., Penninger, J.M., Jackson, A.P., Knoblich, J.A., Cerebral organoids model human brain development and microcephaly. Nature 501 (2013), 373–379.
14. Lapteva, N., Szmania, S.M., van Rhee, F., Rooney, C.M., Clinical grade purification and expansion of natural killer cells. Crit. Rev. Oncog. 19 (2014), 121–132.
15. Leung, W., Infusions of allogeneic natural killer cells as cancer therapy. Clin. Cancer Res. 20 (2014), 3390–3400.
16. Lim, O., Jung, M.Y., Hwang, Y.K., Shin, E.C., Present and future of allogeneic natural killer cell therapy. Front. Immunol., 6, 2015, 286.
17. McCullar, V., Oostendorp, R., Panoskaltsis-Mortari, A., Yun, G., Lutz, C.T., Wagner, J.E., Miller, J.S., Mouse fetal and embryonic liver cells differentiate human umbilical cord blood progenitors into CD56-negative natural killer cell precursors in the absence of interleukin-15. Exp. Hematol. 36 (2008), 598–608.
18. Miller, J.S., Therapeutic applications: natural killer cells in the clinic. Hematol. Am. Soc. Hematol. Educ. Program 2013 (2013), 247–253.
19. Moretta, L., Pietra, G., Montaldo, E., Vacca, P., Pende, D., Falco, M., Del Zotto, G., Locatelli, F., Moretta, A., Mingari, M.C., Human NK cells: from surface receptors to the therapy of leukemias and solid tumors. Front. Immunol., 5, 2014, 87.
20. Murphy, W.J., Parham, P., Miller, J.S., NK cells – from bench to clinic. Biol. Blood Marrow Transpl. 18 (2012), S2–S7.
21. Nakano, T., Ando, S., Takata, N., Kawada, M., Muguruma, K., Sekiguchi, K., Saito, K., Yonemura, S., Eiraku, M., Sasai, Y., Self-formation of optic cups and storable stratified neural retina from human ESCs. Cell Stem Cell 10 (2012), 771–785.
22. Parham, P., MHC class I molecules and KIRs in human history, health and survival. Nat. Rev. Immunol. 5 (2005), 201–214.
23. Tabatabaei-Zavareh, N., Vlasova, A., Greenwood, C.P., Takei, F., Characterization of developmental pathway of natural killer cells from embryonic stem cells in vitro. PLoS One, 2, 2007, e232.
24. Thielens, A., Vivier, E., Romagne, F., NK cell MHC class I specific receptors (KIR): from biology to clinical intervention. Curr. Opin. Immunol. 24 (2012), 239–245.
25. Vey, N., Bourhis, J.H., Boissel, N., Bordessoule, D., Prebet, T., Charbonnier, A., Etienne, A., Andre, P., Romagne, F., Benson, D., et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 120 (2012), 4317–4323.
26. Vodyanik, M.A., Bork, J.A., Thomson, J.A., Slukvin, I.I., Human embryonic stem cell-derived CD34+ cells: efficient production in the coculture with OP9 stromal cells and analysis of lymphohematopoietic potential. Blood 105 (2005), 617–626.
27. Woll, P.S., Martin, C.H., Miller, J.S., Kaufman, D.S., Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity. J. Immunol. 175 (2005), 5095–5103.
28. Woll, P.S., Grzywacz, B., Tian, X., Marcus, R.K., Knorr, D.A., Verneris, M.R., Kaufman, D.S., Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood 113 (2009), 6094–6101.
29. Yang, J., Lam, D.H., Goh, S.S., Lee, E.X., Zhao, Y., Tay, F.C., Chen, C., Du, S., Balasundaram, G., Shahbazi, M., et al. Tumor tropism of intravenously injected human-induced pluripotent stem cell-derived neural stem cells and their gene therapy application in a metastatic breast cancer model. Stem Cells 30 (2012), 1021–1029.
30. Zeng, J., Shahbazi, M., Wu, C., Toh, H.C., Wang, S., Enhancing immunostimulatory function of human embryonic stem cell-derived dendritic cells by CD1d overexpression. J. Immunol. 188 (2012), 4297–4304.
31. Zeng, J., Wang, S., Human dendritic cells derived from embryonic stem cells stably modified with CD1d efficiently stimulate antitumor invariant natural killer T cell response. Stem Cells Transl. Med. 3 (2014), 69–80.
32. Zeng, J., Wu, C., Wang, S., Antigenically modified human pluripotent stem cells generate antigen-presenting dendritic cells. Sci. Rep., 5, 2015, 15262.